Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Growth Metrics
Income Statement
Others
Ratios

Cresco Labs (CRLBF) Accumulated Expenses (2020 - 2025)

Cresco Labs' Accumulated Expenses history spans 6 years, with the latest figure at $58.0 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 6.85% year-over-year to $58.0 million; the TTM value through Dec 2025 reached $58.0 million, up 6.85%, while the annual FY2025 figure was $58.0 million, 6.85% up from the prior year.
  • Accumulated Expenses reached $58.0 million in Q4 2025 per CRLBF's latest filing, up from $54.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $95.4 million in Q4 2021 to a low of $54.3 million in Q4 2024.
  • Average Accumulated Expenses over 5 years is $68.4 million, with a median of $65.2 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: crashed 31.73% in 2022, then grew 6.85% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $95.4 million in 2021, then crashed by 31.73% to $65.2 million in 2022, then grew by 6.01% to $69.1 million in 2023, then fell by 21.4% to $54.3 million in 2024, then increased by 6.85% to $58.0 million in 2025.
  • Per Business Quant, the three most recent readings for CRLBF's Accumulated Expenses are $58.0 million (Q4 2025), $54.3 million (Q4 2024), and $69.1 million (Q4 2023).